THE WORST SYMPTOM VISUAL ANALOGUE SCALE: A PROSPECTIVE ANCILLARY STUDY FROM THE RENAL OPTIMIZATION STRATEGIES EVALUATION IN ACUTE HEART FAILURE (ROSE-AHF) TRIAL
Omar F. AbouEzzeddine(Mayo Clinic), Margaret M. Redfield(Mayo Clinic in Arizona), Adrian F. Hernandez(Duke University), Kevin Anstrom(PragmatIC (United Kingdom)), Eugene Braunwald(Mass General Brigham), Yee Weng Wong(Flinders Medical Centre), Lynne W. Stevenson(Vanderbilt University Medical Center), Peter S. Pang, Steven E. McNulty, Robert J. Mentz(Duke University), Anu Lala(Clinical Research Institute), Javed Butler(Saint Luke's Health System), Michael M. Givertz(Brigham and Women's Hospital), Prateeti Khazanie, Monica Shah(Clinical Research Institute), Marc J. Semigran(Healthwise), Inder S. Anand(University of Minnesota)
Cited by 1
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k